The effects of the Federal Reserve’s recent interest rate cut haven’t fully been felt by the economy or financial markets. But the first instance of U.S. monetary easing in over four years may be a boon for capital-intensive biotech companies. That’s particularly so for those with small- and midcap (SMID) designations. Should that thesis prove [...] The post Tailwinds Emerging for This Biotech ETF appeared first on ETF Trends .